Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.70−0.05 (-6.48%)
Close on Nov 18, 2026Market cap $240.43MP/E –Yield 0.00%
Allogene Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Allogene Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$102.60M. For fiscal 2025 it was -$149.63M. The highest annual figure on record is -$47.89M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$149.63M | – |
| FY2024 | Dec 31, 2024 | -$200.99M | – |
| FY2023 | Dec 31, 2023 | -$239.25M | – |
| FY2022 | Dec 31, 2022 | -$225.71M | – |
| FY2021 | Dec 31, 2021 | -$206.26M | – |
| FY2020 | Dec 31, 2020 | -$181.05M | – |
| FY2019 | Dec 31, 2019 | -$188.14M | – |
| FY2018 | Dec 31, 2018 | -$47.89M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.92M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.93M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$44.54M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$53.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$55.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$62.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$67.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$63.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$47.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$43.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$70.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$46.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$52.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$52.07M | – |
| Q1 FY2021 | Mar 31, 2021 | -$55.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$57.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$42.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$53.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$64.38M | – |
| Q3 FY2019 | Sep 30, 2019 | -$50.34M | – |
| Q2 FY2019 | Jun 30, 2019 | -$32.75M | – |
| Q1 FY2019 | Mar 31, 2019 | -$40.68M | -813680.0% |
| Q4 FY2018 | Dec 31, 2018 | -$22.80M | – |
| Q3 FY2018 | Sep 30, 2018 | -$18.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.58M | – |
| Q1 FY2018 | Mar 31, 2018 | $5.00K | – |
See a number that looks wrong?